INTRODUCTION
Multiple sclerosis (MS) is considered to be an inflammatory demyelinating disease of the central nervous system (CNS), and its etiology remains unclear (Steinman, 1996) . This condition is represented in the well-established animal model for brain inflammation and MS, known as experimental autoimmune encephalomyelitis (EAE), which is a vital tool to study the neuroimmunological events related to the disease (Owens et al., 2001) and resembles many facets of MS (Gold et al., 2006) . (Panitch et al., 1987) , supporting the notion that proinflammatory T helper type 1 (Th1) cell cytokines play a crucial role in the immunopathogenesis of MS. In contrast, the type I interferon beta (IFN-b) reduces the frequency of clinical exacerbations by about 35% and delays the progression of disability in relapsing-remitting MS. Similarly, the lack of the IFN-b gene in mice strongly enhanced the course of EAE (Teige et al., 2003) , and type I interferons can downregulate EAE in mice and rats (Brod and Khan, 1996; Brod and Burns, 1994) , indicating that IFN-b modulates the disease activity in MS and EAE in a similar fashion.
Therapeutic application of interferon gamma (IFN-g) induced acute relapses in MS patients
Regarding the underlying mechanism, earlier studies have suggested several possibilities, including inhibition of Th1 cell development (McRae et al., 1998) , induction of Th2 cell immune deviation (Kozovska et al., 1999) , restoration of function of the disrupted blood-brain barrier (Stone et al., 1995) , and downregulation of IFN-g-induced expression of class II major histocompatibility complex (MHC) molecules on CNS cells (Satoh et al., 1995) . In the light of recent data on IFN-b-induced gene profiles (Satoh et al., 2006; Wandinger et al., 2001) , however, it is generally accepted that IFN-b reveals extremely complex actions that cannot only be reduced to a simple Th2 cell shift (Frohman et al., 2006) .
To date, therapeutic intervention using IFN-b is a major treatment option for MS. However, in up to one-third of the cases, the efficiacy of IFN-b therapy ceases after one year, partly because of the fact that many of these patients develop autoantibodies against IFN-b (Waubant et al., 2003) . Furthermore, a substantial proportion of the patients discontinue IFN-b treatment because of multiple serious side effects, such as skin reactions, flu-like symptoms, leukocytopenia, liver dysfunction, depression, elevated suicide rate, and amenorrhea (Neilley et al., 1996) .
These adverse effects stress the need to better understand how IFN-b actually functions on the molecular and cellular level in an in vivo setting. Previous studies relied on simplified in vitro experiments. Progress with the EAE model, on the other hand, was hampered by the fact that the respective receptor of type 1 interferons (IFN-as and IFN-b), IFNAR, is broadly expressed by virtually all cell types and tissues, including immune cells (Pogue et al., 2004) , endothelial cells (Floris et al., 2002) , and CNS-resident neurons and glia (Okada et al., 2005; Heine et al., 2006) .
To identify the actual cell type targeted by disease-associated IFN-b locally produced in the brain, we conditionally deleted IFNAR from the CNS, lymphocytes, or myeloid cells and studied the pathogenesis of CNS autoimmunity in such mice. Our investigations provide insights into disease-limiting mechanisms that might open new avenues to more cell-specific IFN-b-based therapies minimizing severe adverse effects. Despite being broadly expressed, INFAR was determined to have a unique role on myeloid cells for modulating CNS autoimmunity.
RESULTS

Local IFN-b Production and IFNAR Signaling within the CNS during Autoimmunity
We first assessed endogenous IFN-b production in the CNS and blood of MOG immunized mice by an enzyme-linked immunoabsorbent assay (ELISA) method on day 7, when animals were still free of disease symptoms (score 0), and on day 18, when animals presented with full EAE symptoms (scores > 1.5). Sick individuals showed increased amounts of IFN-b levels in the CNS, whereas IFN-b in the blood of both groups was below the detection limit ( Figure 1A ).
To assess IFNAR signaling triggered by endogenously produced IFN-b, we extracted total RNA from the spinal cord of healthy (score 0), moderately sick (scores 0.5-1.5), and severely affected (scores > 2.5) mice and monitored the expression of IFNARdependent genes by RNA blotting. Even in moderately sick mice, enhanced hybridization signals were found for interferon regulatory factor 1 (IRF1), interferon regulatory factor 7 (IRF7), interferon stimulated gene 15 (ISG 15), and 2 0 ,5 0 oligoadenylatsynthetase (2 0 ,5 0 OAS) ( Figure 1B ). Collectively, these data indicate that even at the onset of the first clinical symptoms, when leukocyte influx can first be monitored, IFN-b is produced locally in the brain in biologically relevant quantities.
Disease-Modulating Role of IFNAR during the Effector Phase of EAE
To examine the impact of IFNAR signaling on the disease course of EAE, we immunized Ifnar1 À/À and wild-type (WT) mice. All animals developed EAE with an incidence of 100% and a similar mean disease onset (Table S1 available online) . However, in Ifnar1 À/À animals, the effector phase of disease was changed dramatically, with an increased lethality rate and an augmented mean maximal clinical score ( Figure 2A , Table S1 , Movies S1 and S2).
IFNAR-deficient spinal cords showed histologically at 35 days after immunization a plethora of infiltrating MAC-3 + macrophages and microglia in the submeningeal and perivascular space, as well as in the CNS parenchyma, which were, upon quantification of the histological sections, significantly upregulated (p < 0.05) ( Figures 2B and 2C right panel) . Importantly, this increased influx of macrophages was accompanied by an invasion of numerically unchanged CD3 + lymphocytes. The myelin damage, however, was increased in Ifnar1 À/À animals ( Figure 2C , left panel, p < 0.05). This distinct pathological infiltration reflected clinical characteristics of Ifnar1 À/À mice showing increased disease burden. Th17 cells are now widely believed to be the main pathogenic population during autoimmune CNS inflammation (Steinman, 2007) . We therefore quantified interleukin-17 (IL-17)-producing myelin oligodendrocyte glycoprotein (MOG)-reactive T cells in (A) Measurement of IFN-b production in the CNS (gray bars) and blood samples (black bars) of immunized, nonsick animals (score 0) or sick animals (score > 1.5). Data represent the means out of four animals in each group ± the standard error of the mean (SEM). (B) RNA blot analysis showing disease-associated induction of IFNAR-dependent genes in the CNS of eight individual mice that are either healthy (immunized, score 0), slightly (score 0.5-1.5) or severely EAE sick (score > 2.5). IFNAR-induced genes were interferon regulatory factor 1 (IRF1), interferon regulatory factor 7 (IRF7), 2 0 -5 0 oligoadenylatsynthetase (2 0 ,5 0 -OAS), and interferon-stimulated gene 15 (ISG15).
Immunity the CNS at day 14 as well as in lymph node cells at days 7 and 14 ( Figure 2D , Figure S1 ). Enzyme-linked immunospot analysis did not show any apparent changes in the IL-17, IL-4, and IFN-g profiles in antigen-specific T cells. For further determination of the impact of IFNAR expression on the cytokine profile within the CNS, mice were sacrificed at the disease peak, and expression of chemoattractant factors and cytokines were examined by real-time polymerase chain reaction (PCR) ( Figure 2E ). Despite a trend toward generally elevated amounts of cytokines in IFNAR-deficient mice, IFN-g, IL-12p35, STAT6, IL-13, TGF-b1, IL-6, and IL-23p19 were not significantly increased, suggesting that more severe EAE in the absence of IFNAR is not linked to a certain Th1, Th2, or Th17 cell bias throughout the disease course. In contrast, chemokines recruiting monocytes and macrophages such as CCL2 and CXCL10 were found to be increased in Ifnar1 À/À mice (p < 0.05). These data revealed that IFNAR is important for the modulation of the effector phase of autoimmunity, and its absence facilitates macrophage invasion into the CNS accompanied by higher demyelination and production of chemokines without shifting the T cell profile.
CNS-Specific IFNAR Expression Is Dispensable for the Induction and Progression of EAE
To assess the role and function of IFNAR during the EAE effector phase, which essentially occurs within the CNS, encephalitogenic MOG-reactive lymphocytes were isolated from WT mice and adoptively transferred into either WT or Ifnar1 À/À recipient mice. Ifnar1 À/À mice developed EAE with earlier disease onset and increased severity, as well as higher incidence rate (p < 0.05, Figure 3 and Table S2 ). These data indicate that IFNAR is involved in the local maintenance of encephalitogenicity during the effector phase of EAE within the CNS. To determine whether IFNAR engagement of CNS-resident cells limits the progression of autoimmune inflammation, we crossed conditional (floxed) IFNAR mice with a transgenic mouse line expressing the Cre recombinase under the control of the nestin promoter. Southern-blot analysis of DNA isolated from different tissues of an Ifnar1 fl/fl NesCre mouse showed efficient deletion of the gene fragment flanked by loxP in the CNS tissue and isolated astrocytes, whereas recombination was absent in the spleen and in primary microglia ( Figure 4A ). Upon immunization, all Ifnar1 fl/fl NesCre mice developed neurological signs of disease such as tail weakness and paralysis, starting about 13-16 days after immunization. ( Figure 4B , Table  S3 ), indicating that the priming phase of disease was unaltered. Furthermore, the mean maximal scores were similar in both groups, suggesting that IFNAR expression on CNS cells is dispensable in EAE. Examination of the CNS revealed no obvious differences in either the pattern of mononuclear infiltration or the amount of macrophages or microglia, and T lymphocytes ( Figure 4C ). Because the Cre transgene is active in all neuroectodermal cells, we also examined disease-associated pathology in axons ( Figure 4D ), oligodendrocytes ( Figure 4E ), and astrocytes ( Figure 4F ) and found no marked changes ( Figures 4D-4F ). Overall, these data indicated that the brain-specific IFNAR is not an essential modulator of the degree and composition of inflammation, demyelination, and axonal damage during sterile autoimmune CNS disease.
IFNAR Engagement on Lymphocytes Has No Impact on T Cell Priming or EAE Development
We further studied the direct impact of IFN-b on lymphocytes in mice with a T cell-specific IFNAR deletion (Ifnar1 fl/fl CD4Cre) and their respective negative littermate controls (Ifnar1 fl/fl ). The analyzed groups developed disease with a similar incidence and a comparable mean disease onset and severity ( Figure 5 , Table  S3 ). Notably, there were 3 days during the priming phase in which T cell-specific Ifnar1 À/À mice had a higher clinical score (p < 0.05, Figure 5B ). Spinal cord sections, however, revealed a comparable amount of macrophages and microglia and T lymphocytes in Ifnar1 fl/fl CD4Cre mice ( Figure 5C ). Accordingly, Figure S3 , Table S3 ). As expected, concomitant CNS pathology was similar in terms of distribution as well as amount of infiltrating macrophages, T lymphocytes, and demyelination ( Figure S3C ). To test whether B cells could produce antigen-specific IL-10 in the absence of IFNAR, we purified splenic B cells from mice that were in the effector phase of EAE. To ensure B cell-receptor crosslinking, we coated tissue-culture wells with MOG 35À55 before adding the purified B cells. B cells incubated with the antigen alone did not produce IL-10. Addition of an agonistic CD40 antibody to the cultures, however, resulted in production of IL-10, which could be further increased in combination with the MOG antigen ( Figure S3D ). Notably, this B cell-specific IL-10 production was independent of the presence of IFNAR. Taken together, these results clearly show that IFNAR engagement on lymphocytes by endogenous type I IFN had no impact on EAE development. Figure S2C ). After immunization of mice, a similar disease onset with a disease incidence comparable to WT mice was observed (Figure 6B, Table S3) . Surprisingly, clinical disease was clearly aggravated during the effector phase in Ifnar1 fl/fl LysMCre mice, leading to a lethality rate of 33%, whereas all Ifnar1 fl/fl mice survived (p < 0.05). Accordingly, the mean clinical score was significantly higher in Ifnar1 fl/fl LysMCre animals (p < 0.05, Figure 6B , Table S3 ). The phenotype of this line largely mirrors the disease course seen in Ifnar1 À/À mice. Importantly, the generation of encephalitogenic MOG-specific T lymphocytes was unaltered even at early time points in Ifnar1 fl/fl LysMCre mice, indicating that LysM expressing IFNAR + cells were not essential for priming ( Figure 6C , Figure S5 ).
We next used quantitative real-time PCR analysis to determine the expression of proinflammatory mediators in the CNS of myeloid cell-specific Ifnar1 À/À mice at the peak of disease ( Figure S6 ). Figure 6D ).
In order to clarify whether engagement of IFNAR on macrophages and microglia modulates CNS pathology, we measured the amount of degraded myelin protein (dMBP) in MAC-3 + macrophages and microglia and found significantly increased numbers of deposits in the absence of IFNAR ( Figure 6E ). To test further whether IFNs can change the uptake of myelin by macrophages, we challenged isolated macrophages with IFN-b in vitro ( Figure 6F ). We found that exogenously added IFN-b was able to modulate myelin uptake by macrophages. Myelin uptake was significantly reduced after incubation with IFN-b, indicating that IFNAR-mediated signaling is a regulator of myelin phagocytosis on cellular level. Further, exogenously added IFNb revealed impaired MHC class II downregulation in IFN-g-stimulated Ifnar1 À/À macrophages that was largely dependent on the presence of Tyk2, a member of the Jak family kinases known to be crucial for the receptor signal transduction by IFNs (Figure 6G ).
To determine how the lack of IFNAR on myeloid cells shapes the immune profile of macrophages, we tested the chemokine pattern in response to the IFN-b inducer LPS alone and in combination with IFN-b ( Figure S7 ). However, when LPS was combined with IFN-b, CXCL1 and CXCL2 production was modulated in WT but not Ifnar1 fl/fl LysMCre macrophages, suggesting that the absence of IFNAR on myeloid cells can cause an enhanced chemokine response. Microglia, the brain-endogenous macrophages, might also be targeted with LysMCre transgenic mice and could therefore also contribute to the IFN-mediated suppression of CNS autoimmunity. Indeed, by performing Southern-blot analysis, we observed a substantial deletion in hematopoietic microglia, whereas neuroectodermal astrocytes were devoid of homologous recombination in the presence of the Cre transgene ( Figure 7A ). Importantly, further in vivo examinations revealed that in the absence of IFNAR signaling, CD11b + Ly-6 lo CD45 lo microglia were a major population within the CNS that expressed MHC class II molecules during EAE ( Figure 7B ). Moreover, Ifnar1 fl/fl LysMCre microglia isolated from the CNS exhibited an altered CXCL2 production capacity in vitro upon LPS stimulation ( Figure 7C ), thereby potentially contributing to the phenotype observed. procedures allowed the identification of 663 significantly regulated genes that were submitted to a k-means clustering analysis with R. This objective method allowed the detection of four different groups of gene induction with clusters 1, 2, and 4 that showed upregulated genes and cluster 3 with downregulated genes ( Figure 7D ). We used the 533 upregulated genes from clusters 1, 2, and 4 for a functional analysis of overrepresentation of Gene Ontology terms in this genes by the GOstats package for R (Falcon and Gentleman, 2007) . The most significant functional group of genes was found to lie within immune or host defense response rather than in the induction of Th1, Th2, or Th17 cell genes. Independent of the gene clusters discussed above, in Table S4 , the most substantially upregulated genes after 6 or 24 hr are shown grouped according to their biological function. Most importantly, many chemokines, cytokines, costimulatory, antigen-presentation molecules, and macrophage-related activation markers were strongly upregulated, whereas no overt upregulation of genes indicative for a Th cell shift were detectable, suggesting a primary innate immune response of macrophages upon IFN-b challenge. Taken together, our data indicate that engagement of myeloidspecific IFNAR by endogenously produced IFN-b modulates the effector but not the priming phase of EAE and leads to aggravated autoimmunity by shaping the innate immune response of myeloid cells, e.g., cytokine and chemokine production, expression of surface immune receptors, and myelin phagocytosis.
DISCUSSION
We addressed here the function of the receptor of type I interferons (IFNAR) in an autoimmune inflammatory mouse model of MS where disease-associated IFN-b is produced locally in the CNS. By using gene-targeted mice, we were able to investigate the role of ubiquitously expressed IFNAR specifically on brain cells as well as on other cell types that participate in EAE pathogenesis, including T and B lymphocytes as well as macrophages and granulocytes. This approach allowed us to identify in vivo the main cell type targeted by interferon action that essentially contributes to CNS autoimmunity.
We found that IFN-b is produced locally in the CNS, but not in the blood, during inflammatory demyelination and that IF-NAR-dependent genes show disease-associated upregulation. Although many cell types are capable of producing type 1 interferons during infection and autoimmunity, the main producers are thought to be plasmacytoid dendritic cells in the blood (Asselin-Paturel et al., 2001; Ito et al., 2006) . However, brain-endogenous cells, e.g., microglia, astrocytes, and neurons, have been shown to produce IFN-b as well (Delhaye et al., 2006; Town et al., 2006 ). It has been described that plasmacytoid DCs, con- ventional DCs, and CD8 alpha + DCs do invade during acute relapsing EAE induced by a proteolipid protein peptide of amino acids 178-191 (Miller et al., 2007) . Nevertheless, the cellular source of disease associated IFN-b production within in the CNS remains to be determined in our MOG EAE model.
In order to test the functional significance of the IFNAR system in the EAE model, we immunized mice lacking IFNAR from all tissues. Importantly, these mice showed an intensified effector phase with increased rate of lethality accompanied by aggravated neuropathological changes, consisting of elevated numbers of invading macrophages and stronger demyelination. Despite higher local production of chemoattractants within the CNS, the number of infiltrating mononuclear cells in the preclinical phase and the ratio of Th cell cytokines remained unchanged. Some results are consistent with a previous observation that mice lacking one ligand of IFNAR, namely IFN-b, developed a more severe MBP 89-101 -induced EAE (Teige et al., 2003) , but in contrast to these earlier findings, we could not detect a substantial increase of the Th1 cell cytokine IFN-g within the CNS of affected mice. Further, our results from the transfer EAE experiments revealed that antigen-restimulated T cells from WT mice induced significantly more disease in IFNAR-deficient animals, indicating that IFNAR expression on host-derived cells is critical for disease induction.
We applied the Cre-LoxP technique to identify the pathogenic role of neuroectoderm-derived CNS host cells, namely astrocytes, oligodendrocytes, and neurons, during EAE. Although it has been shown that astrocytes and oligodendrocytes have proinflammatory properties under several conditions (van Loo et al., 2006) , our results strongly indicate that brain-restricted IFNAR expression does not contribute to the pathogenesis of EAE. Our data are unexpected because previous reports pointed toward a modulating role of IFN-b on astrocytes (Okada et al., 2005; Teige et al., 2006) and oligodendrocytes (Passaquin et al., 1989; Mastronardi et al., 2004) . Despite the fact that our results clearly rule out a disease-modulating role for IFNAR on neuroectodermal cells during EAE, it is still possible that this IFNAR expression might be more important in chronic relapsing EAE models. EAE is a T cell-mediated disease, and it has been reported that IFNAR is expressed on lymphocytes, as well (Pogue et al., 2004) . However, in our study, T cell-restricted Ifnar1 À/À mice developed a similar course of EAE with comparable neuropathological changes. Furthermore, we could not detect any differences in In order to test the hypothesis that IFNAR engagement on myeloid cells is crucial in modulating CNS autoimmunity, we took advantage of the LysM Cre transgenic mouse. Notably, the course of EAE in macrophage-and neutrophil-specific Ifnar1 À/À mice was strongly increased during the effector phase, and some mice even died because of severe disease. The clinical differences to control mice, however, were not always statistically relevant, as seen in the total Ifnar1 À/À situation, most likely due to the fact that gene deletion in myeloid cells is incomplete (Grivennikov et al., 2005) . Which myeloid cell types are crucial in the IFNAR-mediated change of CNS autoimmunity? Although granulocytes have been shown to have immunoregulatory capacity during EAE development (Zehntner et al., 2005) , their number was, in contrast to MAC-3 + mononuclear phagocytes, quite low and not elevated in the CNS (data not shown). The MAC-3 antigen can be found on tissue macrophages, thioglycollate-elicited peritoneal macrophages, and monocytes (Walker et al., 1985) , suggesting that these cells might shape the immmune response within in the CNS. Both CD11b + Ly-6C hi and CD11b + Ly-6C lo monocytes were found to be targeted by the LysM Cre transgene, and therefore these cells might task as endogenous type I interferon-dependent modulators of CNS autoimmunity from the peripheral site. Importantly, professional antigenpresenting cells (APCs) such as plasmacytoid DCs or myeloid DCs were not targeted by the LysM Cre transgene, disproving a role of IFNAR on these cell subsets during sterile autoimmunity of the CNS. Microglia cells are another possible candidate that could suppress inflammatory demyelination in a type I-interferon-dependent manner. They are the brain-endogenous macrophages and populate the CNS early during development to form a regularly spaced network of ramified cells (Priller et al., 2001 ). Microglia become rapidly activated in most pathological conditions of the CNS. In autoimmune diseases such as multiple sclerosis, most experimental results point to a detrimental role of microglia; for example, then can produce neurotoxic molecules, proinflammatory cytokines, and chemokines and can present self-antigens (Steinman, 1996) . How could type I interferons modulate microglia-mediated damage in EAE? Nitric oxide (NO) and its adducts may disrupt CNS tissue integrity (Steinman et al., 2002) , whereas microglia-derived cytokines and chemokines such as TNF and CXCL2 activate and attract blood-derived leukocytes. These may in turn interfere with CNS homeostasis (e.g., by damaging myelin) (Steinman et al., 2002; Hanisch, 2002) . However, effects of IFN-b on production of proinflammatory mediators, such as TNFa, IL-1, or NO, are controversial and seem to be dependent on the mode and conditions of activation (Jin et al., 2007) . Further, reactivation of myelin-specific T cells within the CNS upon recognition of local autoantigens is critical to induce and/or sustain EAE. But it is still debated whether and to what extent microglia present myelin-associated antigens to autoreactive T cells in vivo (Ford et al., 1995) . In vitro, however, it has been demonstrated that IFN-b exerts its beneficial effects also by reducing the antigen-presenting capacity of CNS-specific APCs such as microglia, which in turn inhibits the effector functions of encephalitogenic T cells (Teige et al., 2006) . Interestingly, the lack of IFNAR on CD11b + myeloid cells did not changed the Th cell polarization of T cells in our settings, suggesting that other mechanisms apart from antigen presentation might be vital.
Thus, monocytes and macrophages and their brain-specific equivalent, the microglia, are the IFNAR-dependent myeloid cells critical in shaping CNS autoimmunity. IFNAR signaling in these cells potentially modulates, for example, their activation state. We found a clear increase of MHC class II molecules in the absence of IFNAR, indicating hyperactivation of these cells. These data are in line with previous reports describing a role of IFN-b for MHC class II expression on monocytes in vitro (Kato et al., 1992; Li et al., 1998) .
Our data might provide unique insights into disease-limiting mechanisms of autoimmune inflammation, which might open new avenues toward more cell-specific IFN-b-based therapies that probably would reduce the severity of side effects.
EXPERIMENTAL PROCEDURES Mice
Ifnar1
À/À mice (Muller et al., 1994) originally provided by R. M. Zinkernagel (Zurich, Switzerland) were backcrossed 20 times to C57BL/6. Mice carrying loxP-flanked IFNAR (Kamphuis et al., 2006) were crossed with transgenic mice expressing Cre recombinase under the control of the nestin (Tronche et al., 1999) , CD4 (Wolfer et al., 2001 ), CD19 (Rickert et al., 1997) , or LysM (Clausen et al., 1999) promoter, each backcrossed at least ten times to C57BL/6. All mice were bred in house under pathogen-free conditions.
Induction of EAE
Female 6-to 10-week-old mice from each group were immunized subcutaneously with 200 mg of MOG 35-55 peptide emulsified in CFA containing 1 mg of Mycobacterium tuberculosis (H37RA; Difco Laboratories, Detroit, MI). The mice received intraperitonal injections with 250 ng pertussis toxin (SigmaAldrich, Deisenhofen, Germany) at the time of immunization and 48 hr later.
Adoptive transfer was performed as described (Becher et al., 2001; Prinz et al., 2006) . All animal experiments have been approved by the ethics review board for animal studies at the University of Gö ttingen.
Clinical Evaluation
Mice were scored daily as follows: 0, no detectable signs of EAE; 0.5, distal limb tail; 1.0, complete limb tail; 1.5, limb tail and hind-limb weakness; 2, unilateral partial hind-limb paralysis; 2.5, bilateral partial hind-limb paralysis; 3, complete bilateral hind-limb paralysis; 3.5, complete hind-limb paralysis and unilateral forelimb paralysis; 4, total paralysis of forelimbs and hind limbs; and 5, death.
Histology
Mice were sacrificed with CO 2 . Histology was performed as described recently van Loo et al., 2006) . Spinal cords were removed and fixed in 4% buffered fomalin. Then, spinal cords were dissected and embedded in paraffin before staining with hematoxylin eosin (H&E) or luxol fast blue (LFB) to assess the degree of demyelination, MAC-3 (BD PharMingen) for macrophages and microglia, CD3 for T cells (Serotec, Dü sseldorf, Germany), APP for amyloid precursor protein (Chemicon, Temecula, CA), chloracetate esterase for polymorphonuclear granulocytes (Sigma-Aldrich, Munich Germany), dMPB for degraded myelin basic protein (Chemicon, Temecula, CA), and GFAP for astrocytes (Dako, Hamburg, Germany) .
RNA
Spinal cord tissue was freshly isolated and RNA isolated with TRI-Reagent (Sigma) according to the manufacturer's protocol. RNA (10 mg/lane) was separated on 1% formaldehyde-agarose gels and blotted to positively charged nylon membrane. Probes were radioactively labeled with Rediprime (Amersham) and hybridized with Express-Hyb-Solution (Clontech) according to the manufacturer's protocol.
Flow Cytometry
The cells were stained with primary antibodies directed against Ly-6C, CD45, CD44, MAR1-5A3, CD62L, MHC class II, CD11b, CD4, P-STAT-1, and B220 for 30 min at 4 C. The cells were washed and analyzed with a FACSCalibur (Becton Dickinson). Viable cells were gated by forward and side scatter of light. Data were acquired with CellQuest software (Becton Dickinson).
Postacquisition analysis was perfomed with WinMDI 2.8 software (ScrippsResearch Institute).
Recall Responses, B Cell Activation Assay, IFN-b Measurements, and ELISPOT Analysis Recall assays were performed as described recently . For cytokine analysis, sister cultures were harvested 4 hr after culture supernatants were analyzed by ELISA for IFN-g and IL-17 (R&D Systems, Bergisch-Gladbach, Germany). Spinal cord homogenates were prepared and diluted 1:5 in lysis buffer as described by us (Prinz and Hanisch, 1999) , and IFN-b levels were measured by application of an IFN-b ELISA according to the instructions (PBL Biomedical Laboratories, New Brunswick, NJ). B cell activation was determined as described recently by Fillatreau (Fillatreau et al., 2002) . Enzyme-linked immunospot analysis was performed as reported previously by us .
Peritoneal Macrophages, Microglia, and Stimulation
Mice were injected with thioglycolate (29 g/l phosphate-buffered saline [PBS] ) intraperitoneally (i.p.). Peritoneal cells were collected 96 hr after injection by lavage of the peritoneal cavity with 2 ml of ice-cold PBS. Cells were plated in cellculture plates and nonadhering cells were removed by washing of the wells 1 hr later. Microglia were prepared as described (Prinz and Hanisch, 1999) . Macrophages and microglia were incubated for 24 hr prior to experiments and stimulated with LPS (10 ng/ml), IFN-b (10 ng/ml), and TNFa (10 ng/ml) for 18 hr. Protein levels were detected by ELISA as described by the manufacturer (R&D Systems, Bergisch-Gladbach).
Real-Time PCR and Microarray Analysis RNA was extracted from tissues and flushed with ice-cold HBSS, and RNA was isolated with RNAeasy Mini kits (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. The samples were treated with DNaseI (Roche, Mannheim, Germany), and 1 mg of RNA was transcribed into complementary DNA (cDNA) with oligo-dT primers and the SuperScript II RT kit (Invitrogen, Carlsbad, CA). cDNA (2.5 ml) was transferred into a 96-well Multiply PCR-plate (Sarstedt, Germany), and 12.5 ml ABsolute QPCR SYBR Green master mix (ABgene, Surrey, UK) plus 19.6 ml ddH 2 O was added. The PCR reaction was performed as described recently Mildner et al., 2007) .
Total RNA (1 mg) was processed with the MessageAmp II-Biotion Enhanced Kit (Ambion) and hybridized to the murine array 430 A2.0 according to the manufacturer's protocols (Affymetrix). Microarrays were scanned and initially analyzed with Affymetrix GCOS software. Two biological replicates per condition (0 hr, 6 hr, and 24 hr IFN-b) were carried out. CEL files were processed for global normalization, and expression values were generated with the robust multichip average (rma) algorithm in the R affy package (Bolstad et al., 2003) . So that differential expression could be tested for, the bayesian-adjusted t statistics from the linear models for Microarray data (limma) package with subsequent multiple testing correction based on Benjamini-Hochberg was used (Hochberg and Benjamini, 1990) . Probe sets were considered to be differentially expressed if there was a minimum n-fold change of 3 between any of the three conditions and the p value for 6 hr or 24 hr was below 0.01. ). (white bars) mice. mRNA was extracted at peak of disease and real-time PCR was performed. Data represent mean ± SEM. There are no statistically significant differences. -/-macrophages were exposed to either LPS alone or in combination with IFN-β and production of CXCL2 (MIP-2) and CXCL1 (GROα, KC) was measured by ELISA and compared to LPS-stimulated cells. Data represent mean ± SEM. 
Recipients
The table summarizes data shown in Figure 3 . a of diseased mice. *p<0.05 Selected genes in brain macrophages (microglia) after IFN-β (1.000 U/ml for 6h and 24h) treatment. IFN stimulated genes with a significant change in expression values between IFN-β treated and untreated samples (p-value <0.01) are shown in red. Corresponding Gene Ontology (GO) categories with the respective p-value are derived from a GO overrepresentation analysis for genes in cluster 1, 2 and 4 from Fig. 7D and shown in italics.
